financetom
Business
financetom
/
Business
/
CrowdStrike Holdings Insider Sold Shares Worth $2,021,685, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CrowdStrike Holdings Insider Sold Shares Worth $2,021,685, According to a Recent SEC Filing
Jun 21, 2024 12:50 AM

03:30 AM EDT, 06/21/2024 (MT Newswires) -- Denis O' Leary, Director, on April 19, 2024, sold 5,300 shares in CrowdStrike Holdings ( CRWD ) for $2,021,685. Following the Form 4 filing with the SEC, O' Leary has control over a total of 40,210 shares of the company, with 5,963 shares held directly and 34,247 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1535527/000095010324008605/xslF345X03/dp213123_4-oleary.xml

Price: 382.60, Change: +0.46, Percent Change: +0.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Mama's Creations (MAMA) reported fiscal Q3 diluted earnings late Monday of $0.01 per share, down from $0.05 a year earlier. A single analyst surveyed by FactSet expected $0.03. Revenue for the quarter ended Oct. 31 was $31.5 million, up from $28.7 million a year earlier. Four analysts surveyed by FactSet expected $30 million....
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Merus (MRUS) said Monday the first person has been dosed in its phase 2 trial assessing petosemtamab in heavily pretreated metastatic colorectal cancer. In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC, said Merus Chief Technology Officer John de Kruif. ...
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Robin W.T. Buchanan, Director, on December 13, 2024, executed a purchase for 5,000 shares in Lyondellbasell Industries ( LYB ) for $380,300. Following the Form 4 filing with the SEC, Buchanan has control over a total of 18,175 shares of the company, with 18,175 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1489393/000156218024008417/xslF345X05/primarydocument.xml ...
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Steven I Sarowitz, 10% Owner, Director, on December 12, 2024, sold 20,421 shares in Paylocity Holding ( PCTY ) for $4,138,007. Following the Form 4 filing with the SEC, Sarowitz has control over a total of 8,885,533 shares of the company, with 8,365,533 shares held directly and 520,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1591698/000159169824000427/xslF345X05/wk-form4_1734383554.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved